<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696449</url>
  </required_header>
  <id_info>
    <org_study_id>00000406</org_study_id>
    <secondary_id>31219</secondary_id>
    <nct_id>NCT00696449</nct_id>
  </id_info>
  <brief_title>Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris</brief_title>
  <official_title>An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see how well the drug works for subjects who have
      acne.  Adapalene 0.1% (Differin) will be used in this study to treat your acne.  Differin is
      approved by the Food and Drug Administration (FDA) to treat acne.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent change from baseline in total lesions counts</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of improvement from baseline.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group is considered to be the &quot;standard of care&quot; arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Subjects will treat the face once daily in the evening.
This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>DifferinÂ® Gel, 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Subjects will treat the face once daily in the evening
This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Subjects will treat the face once daily in the evening
n this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Subjects will treat the face once daily in the evening
This group is considered to be the &quot;standard of care&quot; arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Subjects of any race, aged 13 to 18 years inclusive,

          -  Subjects with a diagnosis of moderate to severe Acne vulgaris, measured by lesion
             counts of a minimum of 15 and a maximum of 50 inflammatory lesions (papules and
             pustules) on the face, AND a minimum of 30 and a maximum of 125 total lesions.
             Subjects with nodules may participate in the study.

          -  Female Subjects of childbearing potential must have a negative urine pregnancy test
             (UPT).

          -  Female Subjects of childbearing potential must practice a highly effective method of
             contraception during the study

          -  Subjects (and parent/guardian if Subject is under 18 years of age) must be willing
             and capable of following study instructions to the extent and degree required by the
             protocol;

          -  Subjects able to follow study instructions and likely to complete all required
             visits;

          -  Subjects/Representative signs the Informed Consent prior to any study procedures.
             Subjects under the age of 18 must have one parent or guardian read and sign the
             Informed Assent Form prior to receiving study treatment but the parent(s) or guardian
             is not required to attend the follow-up visits unless requested;

          -  Subject must be willing to be photographed and sign a release form allowing
             photographs to be used.

        Exclusion Criteria:

          -  Female Subjects who are pregnant, nursing or planning a pregnancy during the study,

          -  Subjects with a condition or who are in a situation which, in the Investigator's
             opinion, may put the Subject at risk, may confound the study results, or may
             interfere with the Subject's participation in the study,

          -  Subjects with known allergy to one of the components of the test products,

          -  Subjects who have participated in another investigational drug or device research
             study within 30 days of enrolment, Subjects with acne conglobata, acne fulminans,
             secondary acne (chloracne, drug-induced acne, etc.), or or severe acne requiring more
             than topical treatment (e.g. oral isotretinoin);

          -  Subjects with a beard or other facial hair that might interfere with study
             assessments;

          -  Subjects with underlying diseases or other dermatological conditions that require the
             use of interfering topical or systemic therapy such as, but not limited to, atopic
             dermatitis, perioral dermatitis or rosacea;

          -  Subjects who are at risk in terms of precautions, warnings, and contra-indication
             (see package insert for Differin Gel, 0.1%);

          -  Subjects who foresee intensive UV exposure during the study (mountain sports, UV
             radiation, sunbathing, etc.);

          -  Subjects with a known history of drug and/or alcohol abuse.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Feldman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences Dermatology</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>June 10, 2008</lastchanged_date>
  <firstreceived_date>June 9, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Steve Feldman, MD PhD</name_title>
    <organization>Wake Forest University Health Sciences</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
